- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT04955561
CO2-Patterns During Hyperoxia and Physical Exercise in COPD
CO2-Patterns During Hyperoxia and Physical Exercise in People With Severe COPD - a Randomized, Double-blind Cross Over Trial
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Rationale:
Carbon dioxide partial pressure (PCO2) varies significantly in patients with advanced chronic obstructive pulmonary disease (COPD). Data from the Swedish LTOT Registry showed that PCO2 is an independent predictor for mortality and that there is a U-shaped relationship. Patients with advanced COPD who are still normocapnic at rest may still develop a clinically relevant, exercise-induced carbon dioxide (CO2) retention during exercise/ activity. It is also known that altered breathing patterns at night in COPD patients can lead to nocturnal hypercapnia, especially during REM sleep. The course of PCO2 cannot be reliably predicted by lung function parameters or resting blood gas analysis. Since exercise tests with blood gas control or nightly PCO2 monitoring are rarely performed in clinical routine, exercise induced CO2 retention often remains undetected. In the literature, there is little information on PCO2 behaviour under everyday conditions (with or without LTOT) such as rest, physical exertion and nightly sleep. Therefore, predictors that could describe the PCO2 patterns are missing. However, one former study by O'Donnel from 2002 showed that the change in CO2 under hyperoxia conditions could provide predictive information for the change in CO2 with exercise.
Objective:
Primary aim of this study is to investigate whether the change of PCO2 during a hyperoxia-test (10l/min O2 at rest) correlates with the change of PCO2 during walking exercise with either a: l/min O2 as prescribed; b: medical air; c: 10l/min O2.
Design:
This study is a randomized, controlled cross-over trial. Following an initial maximal incremental shuttle walk test (ISWT), the participant will perform 3 endurance shuttle walk tests (ESWT) at 85% of the maximum ISWT pace on three consecutive days (24h break between ESWTs). In a randomized order, participants will perform one ESWTs with O2-flow as prescribed (e.g. study day 1), one with medical air (same flow rate as prescribed oxygen) (e.g. study day 2) and one with 10l/min O2 (e.g. study day 3). An additional hyperoxia test (10l/min O2 for ten minutes; at resting condition) will be perfomed on each day prior to performing an ESWT.
Tipo de estudo
Inscrição (Antecipado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Tessa Schneeberger
- Número de telefone: +498652931540 +498652931540
- E-mail: TSchneeberger@Schoen-Klinik.de
Locais de estudo
-
-
-
Schönau am Königssee, Alemanha, 83471
- Recrutamento
- Klinikum Berchtesgadener Land, Schön Kliniken
-
Contato:
- Tessa Schneeberger, MSc
- Número de telefone: 0049 - 8652 - 932730
- E-mail: tschneeberger@schoen-klinik.de
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Filho
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- COPD III/ IV
- 35mmHg < PCO2 <= 55mmHg (under resting conditions, breathing room air)
- Hypoxemia (PaO2<60mmHg) under room air conditions (rest or during exercise) or SpO2 <88% during exercise
- established oxygen therapy or given indication for oxygen therapy
- written informed consent
Exclusion Criteria:
- acute exacerbation of COPD
- exercise limiting cardiac or orthopedic comorbidites
- PaO2 <50mmHg at rest, breathing room air
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição cruzada
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: Randomised to begin with oxygen-supplementation at 10L/min during ESWT
Randomised order of tests starting with the 10L/min O2, during the ESWT followed by prescribed O2 flow rate or medical air in randomised order on seperate days
|
Supplemental O2 at rest of 10 l/min for ten minutes followed by supplemental O2 at the prescribed exercise O2-flow rate during ESWT.
Supplemental O2 at rest of 10 l/min for ten minutes followed by medical Air at prescribed O2 flow rate during ESWT.
Supplemental O2 at rest of 10 l/min for ten minutes followed by 10L/min O2 during ESWT.
|
Experimental: Randomised to begin with medical air supplementation at prescibed O2 flow rate during ESWT
Randomised order of tests starting with the medical air during the ESWT followed by prescribed O2 flow rate or 10L/min O2 in randomised order on seperate days
|
Supplemental O2 at rest of 10 l/min for ten minutes followed by supplemental O2 at the prescribed exercise O2-flow rate during ESWT.
Supplemental O2 at rest of 10 l/min for ten minutes followed by medical Air at prescribed O2 flow rate during ESWT.
Supplemental O2 at rest of 10 l/min for ten minutes followed by 10L/min O2 during ESWT.
|
Experimental: Randomised to begin with oxygen supplementation at prescibed O2 flow rate during ESWT
Randomised order of tests starting with the prescribed O2 flow rate, during the ESWT followed by 10L/min O2 or medical air in randomised order on seperate days
|
Supplemental O2 at rest of 10 l/min for ten minutes followed by supplemental O2 at the prescribed exercise O2-flow rate during ESWT.
Supplemental O2 at rest of 10 l/min for ten minutes followed by medical Air at prescribed O2 flow rate during ESWT.
Supplemental O2 at rest of 10 l/min for ten minutes followed by 10L/min O2 during ESWT.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Change in PCO2 during hyperoxia at rest
Prazo: Change from baseline to after 10 minutes breathing 10L/min oxygen
|
pCO2 measured by capillary blood gases taken before and after the hyperoxia test
|
Change from baseline to after 10 minutes breathing 10L/min oxygen
|
Change in PCO2 from rest to end exercise (endurance shuttle walk test)
Prazo: Change from baseline to the end of the ESWT, up to 20 minutes
|
pCO2 measured by capillary blood gases taken before and after the ESWT
|
Change from baseline to the end of the ESWT, up to 20 minutes
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Transcutaneous partial pressure of CO2 (TcPCO2) during hyperoxia test
Prazo: Continuously from baseline to 10 minutes breathing 10L/min oxygen
|
TcPCO2 measured by continuous transcutaneous recording via Sentec-Digital Monitor® (Sentec, Therwil, Switzerland)
|
Continuously from baseline to 10 minutes breathing 10L/min oxygen
|
Transcutaneous partial pressure of CO2 (TcPCO2) during endurance shuttle walk test
Prazo: Continuously during ESWT, up to 20 minutes
|
TcPCO2 measured by continuous transcutaneous recording via Sentec-Digital Monitor® (Sentec, Therwil, Switzerland)
|
Continuously during ESWT, up to 20 minutes
|
Breathing frequency during hyperoxia test
Prazo: Continuously from baseline to 10 minutes breathing 10L/min oxygen
|
Breathing frequency during the hyperoxia test measured by ApneaLink Air™ (ResMed)
|
Continuously from baseline to 10 minutes breathing 10L/min oxygen
|
Breathing frequency during endurance shuttle walk test
Prazo: Continuously during ESWT, up to 20 minutes
|
Breathing frequency during the ESWT measured by ApneaLink Air™ (ResMed)
|
Continuously during ESWT, up to 20 minutes
|
Heart rate during endurance shuttle walk test
Prazo: Continuously during ESWT, up to 20 minutes
|
Heart rate measured by continuous transcutaneous recordung via Sentec-Digital Monitor® (Sentec, Therwil, Switzerland)
|
Continuously during ESWT, up to 20 minutes
|
Heart rate during hyperoxia test
Prazo: Continuously from baseline to 10 minutes breathing 10L/min oxygen
|
Heart rate measured by continuous transcutaneous recordung via Sentec-Digital Monitor® (Sentec, Therwil, Switzerland)
|
Continuously from baseline to 10 minutes breathing 10L/min oxygen
|
Change of capillary partial pressure of O2 (pO2) during endurance shuttle walk test
Prazo: Change from baseline to the end of the ESWT, up to 20 minutes
|
pO2 measured by capillary blood gases taken before and after the ESWT
|
Change from baseline to the end of the ESWT, up to 20 minutes
|
Change of inspiratory capacity during endurance shuttle walk test
Prazo: Change from baseline to the end of the ESWT, up to 20 minutes
|
IC measured by SpiroSense (Pari) before and after the ESWT
|
Change from baseline to the end of the ESWT, up to 20 minutes
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Antecipado)
Conclusão do estudo (Antecipado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- CO2-Hyperoxia & Exercise
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- CIF
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em DPOC
-
Fraunhofer-Institute of Toxicology and Experimental...Institute for Pharmacology and Toxicology, RWTH AachenConcluídoVoluntários Saudáveis | COPD GOLD I a IV | Asma GINA 1 a 4Alemanha
Ensaios clínicos em Oxygen therapy
-
Christopher BellRespirogen Inc.Retirado
-
Pamukkale UniversityConcluído
-
University of PennsylvaniaRescindidoInfecção Recorrente por Clostridium DifficileEstados Unidos
-
Singapore General HospitalSinghealth FoundationDesconhecidoAtividade física | Parada respiratória | Terapia de exercícios | Terapia de Inalação de OxigênioCingapura
-
Azienda Ospedaliera Universitaria Integrata VeronaConcluído
-
University of Roma La SapienzaConcluídoFalha no implante dentário | Mucosite OralItália
-
University of Applied Sciences and Arts of Southern...Vrije Universiteit Brussel; Universiteit Antwerpen; THIM - die internationale...Concluído
-
NeuroTronik Inc.DesconhecidoInsuficiência Cardíaca AgudaPanamá
-
CellMedX CorporationNutrasource Pharmaceutical and Nutraceutical Services, Inc.Concluído
-
Columbia UniversityRescindido